- |||||||||| telmisartan / Generic mfg.
Journal: Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocyte. (Pubmed Central) - May 15, 2022
GW9662, a PPARγ antagonist, completely blocked pioglitazone (PPARγ agonist)-induced adiponectin secretion and mRNA expression, whereas it unexpectedly blocked neither telmisartan- nor irbesartan-induced adiponectin secretion and mRNA expression but rather increased them...Leptin secretion was not affected by any ARBs at 1 µM and GW9662 significantly decreased the basal secretion of leptin, suggesting that basal leptin secretion is regulated in a PPARγ dependent manner. We conclude that telmisartan is the most effective ARB to increase adiponectin secretion via PPARα without raising leptin secretion from HWAs.
- |||||||||| sirolimus / Generic mfg., pioglitazone / Generic mfg.
Journal: Adipose Rheb deficiency promotes miR-182-5p expression via the cAMP/PPARγ signaling pathway. (Pubmed Central) - May 14, 2022
Our study reveals a unique mechanism by which Rheb regulates miR-182-5p in adipocytes. Given that increasing miR-182-5p in adipose tissue promotes beige fat development, our study also suggests a unique mechanism by which Rheb promotes thermogenesis and energy expenditure.
- |||||||||| nitroprusside / Generic mfg., losartan potassium / Generic mfg., pioglitazone / Generic mfg.
Preclinical, Journal: RAS Imbalances Account for Baroreflex Dysfunction and Neuroinflammation Induced by Postpartum Endotoxemia in Weaning Preeclamptic Rats. (Pubmed Central) - May 14, 2022
These effects were distinctly affected by gestational therapies as Ang 1-7 reversed the altered brainstem expression of TLR-4/ACE2, while gestational losartan/pioglitazone reversed the augmented ACE expression. Together, gestational targeting of offensive (ACE/Ang II (suppression) and defensive (ACE2/Ang 1-7, facilitation) arms of RAS offers a reprogramming strategy against brainstem neuroinflammation and consequent baroreceptor depression caused by endotoxemia in weaning PE dams.
- |||||||||| pioglitazone / Generic mfg.
Preclinical, Journal: Pharmacological Evaluation of Beta-Hydroxifosphocarnitine in No-Alcoholic Esteatohepatitis Induced in Rats. (Pubmed Central) - May 14, 2022
Together, gestational targeting of offensive (ACE/Ang II (suppression) and defensive (ACE2/Ang 1-7, facilitation) arms of RAS offers a reprogramming strategy against brainstem neuroinflammation and consequent baroreceptor depression caused by endotoxemia in weaning PE dams. β-HFC has an effect on improving liver and metabolic alterations characteristic of the development of NASH.
- |||||||||| imatinib / Generic mfg., pioglitazone / Generic mfg.
KINETICS OF CITED2 GENE EXPRESSION IN CHRONIC MYELOID LEUKEMIA PATIENTS () - May 13, 2022 - Abstract #EHA2022EHA_1314;
Conclusion Pioglitazone in combination with imatinib improved the patients’ response and downregulate the expression of the CITED2 overexpressed gene. Longer follow up is planned and needed to confirm whether it can effectively induce more deep molecular response among the patients or not.
- |||||||||| pioglitazone / Generic mfg.
Oral Long-Acting Menin Inhibitor Normalizes Type 2 Diabetes Mellitus (T2DM) in Two Rat Models (Poster Hall (Halls D-E); Board No. 851) - May 11, 2022 - Abstract #ADA2022ADA_1557;
Rats were treated daily with BMF-219, vehicle, or pioglitazone for 16 days...Significant reductions in blood lipemic levels (p<0.01) and body weight were observed in both models. Collectively, our data indicate the novel and marked potential of BMF-219 as an oral, long-acting treatment for T2DM.
- |||||||||| pioglitazone / Generic mfg.
Journal: Mechanism of Tibetan medicine Ershiwuwei Songshi Pills in regulating intestinal flora and improving non-alcoholic steatohepatitis (Pubmed Central) - May 10, 2022
Forty-eight male C57 BL/6 mice were randomly divided into the control group, model(methionine-choline-deficient, MCD) group, high-(0.8 g·kg~(-1)), medium-(0.4 g·kg~(-1)), and low-dose(0.2 g·kg~(-1)) ESP groups, and pioglitazone(PGZ, 10 mg·kg~(-1)) group, with eight mice in each group...In the alteration of the composition of intestinal flora, ESP reduced the abundance of Erysipelotrichia and Faecalibaculum but increased the abundance of Desulfovibrionaceae, Rikenellaceae, Lachnospiraceae, and Ruminococcaceae. This study has revealed that ESP has a protective effect against NASH induced by MCD diet, which may be related to its regulation of the changes in intestinal flora, alteration of the composition of intestinal flora, and inhibition of the intestinal dysbiosis.
- |||||||||| pioglitazone / Generic mfg.
Trial completion date, Trial primary completion date: Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - May 9, 2022
P1, N=36, Recruiting,
This study has revealed that ESP has a protective effect against NASH induced by MCD diet, which may be related to its regulation of the changes in intestinal flora, alteration of the composition of intestinal flora, and inhibition of the intestinal dysbiosis. Trial completion date: Dec 2021 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| Journal: Effects of systemic drugs on the development of drug-induced retinopathy (Pubmed Central) - May 7, 2022
The limitation and the conditions of applicability for this approach are discussed in detail. This article reviews information on possible adverse events occurring in the organ of vision - in particular, the retina - after using systemic drugs, discusses the drugs that lead to drug-induced retinopathy most often, and describes histomorphological changes and modern understanding of the pathogenesis of damage to retinal structures.
- |||||||||| erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
Journal: Activation of the PPARγ Prevents Ferroptosis-Induced Neuronal Loss in Response to Intracerebral Hemorrhage Through Synergistic Actions With the Nrf2. (Pubmed Central) - May 7, 2022
The results showed that PDZ inhibited ferroptosis in neurons by increasing the expression of PPARγ, Nrf2 and Gpx4 in vitro, while PDZ reduced ferroptosis in neurons after ICH and promoted the recovery of neural function in vivo. Our results suggest that PDZ, a PPARγ agonist, promotes Gpx4 expression through the interaction between PPARγ and the Nrf2 pathway, inhibits ferroptosis of neurons after ICH, and promotes the recovery of neural function.
- |||||||||| pioglitazone / Generic mfg.
Using Computational Approaches for Predictive Models of Antidepressant Response: Integrating Biological Networks With Clinical Outcomes () - May 6, 2022 - Abstract #SOBP2022SOBP_297;
These improvements were associated with the receptor-independent actions of PIO and the mechanism of action of PIO did not appear to be affected by the PPAR-γ receptor in broiler breeder roosters. The findings of multidimensional signatures involved in the pathophysiology of depression and their role in predicting antidepressant outcomes provide a starting point for development of a mechanistic framework linking biological networks and environmental factors to clinical outcomes in pursuit of more effective personalized medicine strategies.
- |||||||||| pioglitazone / Generic mfg., acarbose / Generic mfg.
Review, Journal: Effects of Diet and Antihyperglycemic Drugs on Erectile Dysfunction: A Systematic Review. (Pubmed Central) - Apr 30, 2022
The findings of multidimensional signatures involved in the pathophysiology of depression and their role in predicting antidepressant outcomes provide a starting point for development of a mechanistic framework linking biological networks and environmental factors to clinical outcomes in pursuit of more effective personalized medicine strategies. Although encouraging results are present for all classes of antihyperglycemic drugs, several studies are needed in humans, mainly on acarbose, pioglitazone, dipeptidyl-peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial initiation date: Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis (clinicaltrials.gov) - Apr 28, 2022
P4, N=160, Not yet recruiting,
Although encouraging results are present for all classes of antihyperglycemic drugs, several studies are needed in humans, mainly on acarbose, pioglitazone, dipeptidyl-peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Initiation date: Mar 2022 --> Jun 2022
- |||||||||| Trial completion date, Trial primary completion date: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Apr 28, 2022
P=N/A, N=150, Active, not recruiting,
Initiation date: Mar 2022 --> Jun 2022 Trial completion date: Oct 2021 --> Oct 2023 | Trial primary completion date: Oct 2021 --> Oct 2023
- |||||||||| pioglitazone / Generic mfg.
Preclinical, Journal: PPARγ Agonist Attenuates Vocal Fold Fibrosis in Rats via Regulation of Macrophage Activation. (Pubmed Central) - Apr 27, 2022
This study aimed to evaluate the effects of pioglitazone (PIO), a PPARγ agonist, on the macrophage phenotype and fibrosis following vocal fold injury in rats...These results indicate that PPARγ activation could inhibit accumulation of inflammatory macrophages and improve tissue repair. Considered together, these findings imply that inflammatory macrophages play a key role in vocal fold fibrosis.
- |||||||||| pioglitazone / Generic mfg., gliclazide / Generic mfg.
Biomarker, Clinical, Journal: Net benefit index: Assessing the influence of a biomarker for individualized treatment rules. (Pubmed Central) - Apr 26, 2022
To account for sampling uncertainty in assessing a biomarker, we propose an NBI-based test for a significant improvement over the existing ITR, where the empirical null distribution is constructed via the method of stratified permutation by treatment arms. Applying NBI to the motivating diabetes trial, we found that baseline fasting insulin is an important biomarker that leads to an improvement over an existing ITR based only on patient's baseline fasting plasma glucose (FPG), age and body mass index (BMI) to reduce FPG over a period of 52 weeks' treatment.
- |||||||||| pioglitazone / Generic mfg.
AN OPEN-LABEL TRIAL OF THE PPAR-γ LIGAND PIOGLITAZONE FOR IDIOPATHIC GASTROPARESIS: A FIRST STEP TOWARDS DISEASE MODIFYING THERAPY (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_1615;
P1
Conclusion : In this pilot hypothesis-generating trial, open-label administration of pioglitazone was associated with an improvement in gastroparesis symptoms, suggesting a role for it in the treatment of IG, possibly by its known effects on macrophage activation. While a randomized, double-blind, placebo-controlled trial of pioglitazone for IG is still needed, these findings point to the possibility of effective disease-modifying medication for this disorder for the first time.
- |||||||||| pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
Journal: Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation. (Pubmed Central) - Apr 23, 2022
Herein we report the discovery by virtual screening of 10, which is a potent PPARγ binder and in vitro inhibitor of the CDK5-mediated phosphorylation of PPARγ Ser273 and displays negligible PPARγ agonism in a reporter gene assay. The pharmacokinetic properties of 10 are compatible with oral dosing, enabling preclinical in vivo testing, and a 7 day treatment demonstrated an improvement in insulin sensitivity in the ob/ob diabetic mouse model.
- |||||||||| Clinical, Review, Journal: Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. (Pubmed Central) - Apr 21, 2022
Pioglitazone, lanifibranor, and GLP1-R agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH (ie, steatosis, ballooning, lobular inflammation) or achieved resolution of NASH without worsening of fibrosis. SGLT2 inhibitors (mostly empagliflozin and dapagliflozin) reduced liver fat content, as assessed by magnetic resonance-based techniques.
- |||||||||| pioglitazone / Generic mfg.
Review, Journal: SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. (Pubmed Central) - Apr 19, 2022
Among the most studied is pioglitazone, either alone or in combination with vitamin E, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors...Experimental studies in animal models have suggested that SGLT2 inhibitors may have beneficial modulatory effects on NAFLD/NASH, and several trials in patients have proven their beneficial effects on liver enzymes, BMI, blood lipids, blood glucose, and insulin resistance in NAFLD patients, thus creating strong expectations for their possible use in preventing the evolution of liver damage in these patients. We will review the main pathogenetic mechanisms, diagnostic modalities, and recent therapies of NAFLD, with particular attention to the use of SGLT2 inhibitors.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Journal: JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. (Pubmed Central) - Apr 19, 2022
Some medications approved for the treatment of type 2 diabetes may reduce liver fat (SGLT2 inhibitors, insulin) or even reverse steatohepatitis in paired liver biopsy studies (GLP-1 RAs or pioglitazone) Overall the field of preventive metabolic medicine is expanding. Clinical lipidologists should become familiar with recent advances.
- |||||||||| pioglitazone / Generic mfg.
Journal: Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition. (Pubmed Central) - Apr 19, 2022
We undertook longitudinal β-amyloid positron emission tomography (Aβ-PET) imaging as a translational tool for monitoring of chronic treatment with the peroxisome proliferator-activated receptor gamma (PPARγ) agonist pioglitazone in Aβ model mice...These translational data suggest that a shift toward higher plaque fibrillarity protects cognitive function and brain integrity. Increases in the Aβ-PET signal upon immunomodulatory treatments targeting Aβ aggregation can thus be protective.
- |||||||||| Piqray (alpelisib) / Novartis
Review, Journal: Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. (Pubmed Central) - Apr 13, 2022
Lifestyle modifications, mainly comprising a reduced-carbohydrate diet, and a designated stepwise, personalized antihyperglycemic regimen, based on metformin, sodium-glucose co-transporter 2 inhibitors, and pioglitazone, are the main tools required to address the insulin-resistant hyperglycemia induced by alpelisib. In this report, based on the consensus of 14 oncologists and seven endocrinologists, we provide guidance for hyperglycemia management strategies before, during, and after alpelisib therapy for HR+, HER2-, PIK3CA-mutated breast cancer, with a focus on a proactive, multidisciplinary approach.
|
